Study of immunotherapy for colorectal and endometrial cancer
Treatments studied
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have colorectal or endometrial cancer that has spread or come back and cannot be removed by surgery.
- Your tumor has a specific genetic feature (MSI-H/dMMR for one group, or MSS/pMMR for the other).
- You must have at least one tumor that can be biopsied (a small sample taken) and another tumor that can be measured on scans.
- You have not had certain immunotherapy drugs before (like anti-PD-1 or anti-CTLA-4).
- You are willing to use effective birth control if there is a chance of pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This study looks at how well two drugs, durvalumab and olaparib, work together after initial chemotherapy for advanced or recurrent endometrial cancer. It may help patients who have not had many treatment options before.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan and cetuximab, for people with colorectal cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug (VVD-133214) combined with an existing immunotherapy (pembrolizumab) for advanced colorectal cancer that is mismatch repair deficient. It aims to see if the combination works better than pembrolizumab alone in shrinking or controlling the cancer.
This trial tests giving immunotherapy (a drug that boosts your immune system to fight cancer) with or without radiation before surgery for colorectal cancer that is MSI-High or dMMR. It aims to see if this approach can shrink tumors and improve outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.